Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial

Sulggi A. Lee, Julian H. Elliott, James McMahon, Wendy Hartogenesis, Namandje N. Bumpus, Jeffrey D. Lifson, Robert J. Gorelick, Peter Bacchetti, Steven G. Deeks, Sharon R. Lewin, Radojka M. Savic

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Disulfiram (DSF) was well tolerated and activated viral transcription (cell-associated unspliced (CA-US) and plasma human immunodeficiency virus (HIV) RNA) in a phase II dose-escalation trial in HIV+ antiretroviral therapy (ART)-suppressed participants. Here, we investigated whether exposure to DSF and its metabolites predicted these changes in HIV transcription. Participants were administered 500 (N = 10), 1,000 (N = 10), or 2,000 (N = 10) mg of DSF for 3 consecutive days. DSF and four metabolites were measured by ultraperformance liquid chromatography-tandem mass spectrometry. Changes in CA-US and plasma HIV RNA were quantified by polymerase chain reaction (PCR) and analyzed in NONMEM. A seven-compartment pharmacokinetic (PK) model demonstrated nonlinear elimination kinetics. The fitted median area under the curve values for 72 hours (AUC 0–72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively. Higher exposure predicted greater increases in CA-US (maximum effect (E max ) = 78%, AUC 50  = 1,600 μg*hour/L, P = 0.013) but not plasma HIV RNA. These results provide support for further development of DSF as an important drug for future HIV cure strategies.

Original languageEnglish
Pages (from-to)692-702
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume105
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

Cite this

Lee, Sulggi A. ; Elliott, Julian H. ; McMahon, James ; Hartogenesis, Wendy ; Bumpus, Namandje N. ; Lifson, Jeffrey D. ; Gorelick, Robert J. ; Bacchetti, Peter ; Deeks, Steven G. ; Lewin, Sharon R. ; Savic, Radojka M. / Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. In: Clinical Pharmacology and Therapeutics. 2019 ; Vol. 105, No. 3. pp. 692-702.
@article{6936e252df49491f8a94b797070bfc70,
title = "Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial",
abstract = "Disulfiram (DSF) was well tolerated and activated viral transcription (cell-associated unspliced (CA-US) and plasma human immunodeficiency virus (HIV) RNA) in a phase II dose-escalation trial in HIV+ antiretroviral therapy (ART)-suppressed participants. Here, we investigated whether exposure to DSF and its metabolites predicted these changes in HIV transcription. Participants were administered 500 (N = 10), 1,000 (N = 10), or 2,000 (N = 10) mg of DSF for 3 consecutive days. DSF and four metabolites were measured by ultraperformance liquid chromatography-tandem mass spectrometry. Changes in CA-US and plasma HIV RNA were quantified by polymerase chain reaction (PCR) and analyzed in NONMEM. A seven-compartment pharmacokinetic (PK) model demonstrated nonlinear elimination kinetics. The fitted median area under the curve values for 72 hours (AUC 0–72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively. Higher exposure predicted greater increases in CA-US (maximum effect (E max ) = 78{\%}, AUC 50  = 1,600 μg*hour/L, P = 0.013) but not plasma HIV RNA. These results provide support for further development of DSF as an important drug for future HIV cure strategies.",
author = "Lee, {Sulggi A.} and Elliott, {Julian H.} and James McMahon and Wendy Hartogenesis and Bumpus, {Namandje N.} and Lifson, {Jeffrey D.} and Gorelick, {Robert J.} and Peter Bacchetti and Deeks, {Steven G.} and Lewin, {Sharon R.} and Savic, {Radojka M.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/cpt.1220",
language = "English",
volume = "105",
pages = "692--702",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "American Society for Clinical Pharmacology and Therapeutics",
number = "3",

}

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. / Lee, Sulggi A.; Elliott, Julian H.; McMahon, James; Hartogenesis, Wendy; Bumpus, Namandje N.; Lifson, Jeffrey D.; Gorelick, Robert J.; Bacchetti, Peter; Deeks, Steven G.; Lewin, Sharon R.; Savic, Radojka M.

In: Clinical Pharmacology and Therapeutics, Vol. 105, No. 3, 01.03.2019, p. 692-702.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial

AU - Lee, Sulggi A.

AU - Elliott, Julian H.

AU - McMahon, James

AU - Hartogenesis, Wendy

AU - Bumpus, Namandje N.

AU - Lifson, Jeffrey D.

AU - Gorelick, Robert J.

AU - Bacchetti, Peter

AU - Deeks, Steven G.

AU - Lewin, Sharon R.

AU - Savic, Radojka M.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Disulfiram (DSF) was well tolerated and activated viral transcription (cell-associated unspliced (CA-US) and plasma human immunodeficiency virus (HIV) RNA) in a phase II dose-escalation trial in HIV+ antiretroviral therapy (ART)-suppressed participants. Here, we investigated whether exposure to DSF and its metabolites predicted these changes in HIV transcription. Participants were administered 500 (N = 10), 1,000 (N = 10), or 2,000 (N = 10) mg of DSF for 3 consecutive days. DSF and four metabolites were measured by ultraperformance liquid chromatography-tandem mass spectrometry. Changes in CA-US and plasma HIV RNA were quantified by polymerase chain reaction (PCR) and analyzed in NONMEM. A seven-compartment pharmacokinetic (PK) model demonstrated nonlinear elimination kinetics. The fitted median area under the curve values for 72 hours (AUC 0–72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively. Higher exposure predicted greater increases in CA-US (maximum effect (E max ) = 78%, AUC 50  = 1,600 μg*hour/L, P = 0.013) but not plasma HIV RNA. These results provide support for further development of DSF as an important drug for future HIV cure strategies.

AB - Disulfiram (DSF) was well tolerated and activated viral transcription (cell-associated unspliced (CA-US) and plasma human immunodeficiency virus (HIV) RNA) in a phase II dose-escalation trial in HIV+ antiretroviral therapy (ART)-suppressed participants. Here, we investigated whether exposure to DSF and its metabolites predicted these changes in HIV transcription. Participants were administered 500 (N = 10), 1,000 (N = 10), or 2,000 (N = 10) mg of DSF for 3 consecutive days. DSF and four metabolites were measured by ultraperformance liquid chromatography-tandem mass spectrometry. Changes in CA-US and plasma HIV RNA were quantified by polymerase chain reaction (PCR) and analyzed in NONMEM. A seven-compartment pharmacokinetic (PK) model demonstrated nonlinear elimination kinetics. The fitted median area under the curve values for 72 hours (AUC 0–72 ) were 3,816, 8,386, and 22,331 mg*hour/L, respectively. Higher exposure predicted greater increases in CA-US (maximum effect (E max ) = 78%, AUC 50  = 1,600 μg*hour/L, P = 0.013) but not plasma HIV RNA. These results provide support for further development of DSF as an important drug for future HIV cure strategies.

UR - http://www.scopus.com/inward/record.url?scp=85054652026&partnerID=8YFLogxK

U2 - 10.1002/cpt.1220

DO - 10.1002/cpt.1220

M3 - Article

VL - 105

SP - 692

EP - 702

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -